Mostrar el registro sencillo del ítem

dc.contributor.authorFlores-Burgess, Antonio 
dc.contributor.authorPineda-Gómez, Juan Pedro
dc.contributor.authorMillón-Peñuela, Carmelo 
dc.contributor.authorGago-Calderón, Belén 
dc.contributor.authorGarcía-Durán, Laura 
dc.contributor.authorCantero-García, Noelia
dc.contributor.authorPuigcerver-Martínez, Araceli 
dc.contributor.authorNarváez-Bueno, José Ángel 
dc.contributor.authorFuxe, Kjell
dc.contributor.authorSantín-Núñez, Luis Javier 
dc.contributor.authorDíaz-Cabiale, Zaida 
dc.date.accessioned2022-07-26T08:54:35Z
dc.date.available2022-07-26T08:54:35Z
dc.date.issued2022-07-12
dc.identifier.urihttps://hdl.handle.net/10630/24780
dc.description.abstractMajor depression is the largest contributor to global disability by years lived with disability. Selective serotonergic reuptake inhibitors, including fluoxetine (FLX), are the most commonly used antidepressant for the treatment of major depression. However, they are effective for remission in only 30% of patients. Recently, we observed that the N-terminal fragment of Galanin [GAL(1-15)] enhanced the antidepressant effects of FLX in naïve animals. In this work, we have analyzed in an animal model of depression, the olfactory bulbectomy (OBX) rats, the effect of GAL(1-15) on FLX-mediated responses in the forced swimming test (FST) and the sucrose preference test (SPT), tests related with despair and anhedonic behaviours. We have also studied the corticosterone levels in OBX rats after the coadministration of GAL(1-15)+FLX. Groups of rats received a subchronic pattern of FLX(10mg/Kg) alone or in combination with GAL(1-15)(1nmol)15min before the tests. Blood samples for corticosterone assay were collected 1h after the treatments. One-way ANOVA followed by Fisher ́s least significant difference test was used. Our results show that GAL(1-15) decreases the immobility time by 50% (p<0.05) and increases the swimming time by 30% (p<0.01) compared with FLX in the FST, and in the SPT reversed the effects of the OBX procedure increasing the sucrose intake (p<0.05) and preference (p<0.05). The coadministration of GAL(1-15)(1nmol)+FLX(10mg/kg) also reduced the OBX-increased corticosterone levels by approximately 50% (p<0.05). In conclusion, these novelty results suggest using GAL(1-15) in combination with FLX as a novel strategy fortreating depression.es_ES
dc.description.sponsorshipSupported by Spanish Ministry of Economy PID2020-114392RB-I00, PDC2021-121566-I00; Junta de Andalucia P20_00026, PI-0083-2019 and UMA18-FEDERJA-008. Universidad de Málaga. Campus de Excelencia Internacional Andalucía Teches_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectNeuropsicofarmacología - Congresoses_ES
dc.subjectExperimentación animal - Congresoses_ES
dc.subjectMedicamentos - Ensayos - Congresoses_ES
dc.subjectMedicamentos - Efectividad - Congresoses_ES
dc.subjectDepresión mental - Congresoses_ES
dc.subject.otherDepressiones_ES
dc.subject.otherFluoxetinees_ES
dc.subject.otherGalanin(1-15)es_ES
dc.subject.otherOlfatory bulbectomy ratses_ES
dc.titleNew augmentation strategy in depression: Galanin (1-15) enhances the behavioral effects of Fluoxetine in the olfactory bulbectomy rat.es_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Medicinaes_ES
dc.relation.eventtitleFENS FORUM 2022es_ES
dc.relation.eventplaceParís, Franciaes_ES
dc.relation.eventdate09/07/22 - 13/07/22es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem